

**Form 603**

Corporations Act 2001

Section 671B

**Notice of initial substantial holder**To Company Name/Scheme **Firebrick Pharma Limited (Firebrick)**ACN/ARSN **157 765 896****1. Details of substantial holder (1)**Name **Firebrick Pharma Limited**ACN/ARSN (if applicable) **157 765 896**

The holder became a substantial holder on

First became a substantial holder in relation to the escrow arrangements referred to in this notice on 18 January 2022 as a result of the issue of ordinary shares (Shares) in Firebrick that completed on 18 January 2021 as described in the prospectus lodged by Firebrick with ASIC on 26 November 2021 (Propsectus).

This notice describes the voting power and relevant interests of the substantial holder as at 18/01/2022

**2. Details of voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
<b>Ordinary Shares</b>	<b>62,732,537</b>	<b>62,732,537</b>	<b>37.15%</b>

**3. Details of relevant interests**

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
<b>Firebrick Pharma Limited</b>	<b>Restrictions on the disposal of shares under the mandatory escrow arrangements that were disclosed in the Prospectus give Firebrick a technical 'relevant interest' in its own shares under section 608(1)(c) of the Corporations Act. Firebrick has no right to acquire these shares or to control the voting rights attaching to these shares. Annexure A contains a summary of the relevant escrow arrangements. Annexure B contains a proforma copy of the escrow deed executed by the persons described in Annexure A.</b>	<b>Ordinary shares - 62,732,537</b>

**4. Details of present registered holders**

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
<b>Firebrick</b>	<b>Those persons described in Annexure A</b>	<b>Those persons described in Annexure A</b>	<b>See Annexure A</b>

### 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
<b>Firebrick</b>	<b>N/A</b>		<b>No consideration was paid by Firebrick for the relevant interests described in paragraph 3 above. Firebrick has no right to acquire the shares that are subject to the relevant escrow arrangements.</b>	<b>N/A</b>

### 6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
<b>N/A</b>	<b>N/A</b>

### 7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
<b>Firebrick Pharma Limited</b>	<b>Level 10, 440 Collins Street, Melbourne VIC 3000</b>

### Signature

print name

**PETER L MOLLOY**

capacity

**Executive Chairman**

sign here



date

**20 / 01 /2022**


**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
  - (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
  - (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
  - (4) The voting shares of a company constitute one class unless divided into separate classes.
  - (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
  - (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
  - (7) Include details of:
    - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
    - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
- See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option) write "unknown".
  - (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
-

## Annexure A – Summary of escrow arrangements

This is Annexure A of 1 page referred to in Form 603 (Notice of initial substantial holder) given by Firebrick Pharma Limited


Print name: Peter L Molloy Capacity: Executive Chairman

Sign here:  Date: 20/01/2022

Holder	Controller (if relevant)	Escrowed until	Total number of escrowed shares
Aquarico Pty Ltd ACN 604 618 260	Peter Laurence Molloy	18/01/2024	30,054,412
Biotech Design Pty Ltd ACN 097 086 701	Stephen Francis Goodall	18/01/2024	30,054,412
Kashflow 18 LLC	Peter Kash	18/01/2024	2,103,713
Phyllis Gardner	N/A	18/01/2024	520,000

## Annexure B – Pro forma escrow deed

This is Annexure B of 8 pages referred to in Form 603 (Notice of initial substantial holder) given by Firebrick Pharma Limited

Print name:	<u>Peter L Molloy</u>	Capacity:	<u>Executive Chairman</u>
Sign here:	 <u></u>	Date:	<u>20/01/2022</u>

**FIREBRICK PHARMA LIMITED**  
**ACN 157 765 896**  
**(entity)**

**and**

**[NAME]**  
**(holder)**

---

**RESTRICTION DEED**

---

We, the persons in:

- Item 1 of the schedule (**entity**);
- Item 2 of the schedule (**holder**); and
- Item 3 of the schedule (**controller**),

agree as follows.

---

## INTRODUCTION

---

- A. The entity intends to issue, or has issued, restricted securities to the holder. The holder has agreed to hold the restricted securities as set out in this deed.
- B. We enter into this deed for the purpose of complying with chapter 9 of the listing rules.
- C. We acknowledge that the entity's admission or continued admission to the ASX official list is conditional on the provision of this deed.

---

## ESCROW RESTRICTIONS

---

1. During the escrow period, the holder must not:

- (a) Dispose of, or agree or offer to dispose of, the restricted securities;
- (b) Create, or agree or offer to create, any security interest in the restricted securities; or
- (c) Do, or omit to do, any act if the act or omission would have the effect of transferring effective ownership or control of the restricted securities,

except as permitted in the listing rules or by ASX in writing and anything done in contravention of this clause is not binding on, and will not be recognised as legally effective by, the entity or ASX.

2. During the escrow period, a controller must not:

- (a) Dispose of, or agree or offer to dispose of, the controller interests;
- (b) Create, or agree or offer to create, any security interest in the controller interests; or
- (c) Do, or omit to do, any act if the act or omission would have the effect of transferring effective ownership or control of the controller interests,

except as permitted in the listing rules or by ASX in writing and anything done in contravention of this clause is not binding on, and will not be recognised as legally effective by, the entity or ASX

3. The holder agrees that the restricted securities are to be kept on the entity's issuer sponsored subregister and are to have a holding lock applied for the duration of the escrow period.

---

## WARRANTIES

4. If item 3 of the schedule is completed, the holder and each controller warrant that:
- (a) the holder has the controllers set out in item 3 of the schedule with the controller interests identified in item 6 of the schedule;
  - (b) there are no other controllers or controller interests; and
  - (c) the holder and each controller have provided ASX and the entity with all information necessary to properly form an opinion about who is controller of the holder and who is required to execute this deed.
5. If item 3 of the schedule is not completed or is marked "nil" or "n/a" (or something equivalent), the holder warrants that:
- (a) if the holder is one or more individuals, they are legal and beneficial owner of the restricted securities;
  - (b) if the holder is not one or more individuals, the holder has no controller; and
  - (c) the holder has provided ASX and the entity with all information necessary to properly form an opinion that the holder falls within (a) or (b) above.
6. If item 8 of the schedule is completed, the holder warrants that:
- (a) full particulars of the security interests which have been created over the restricted securities are set out in item 8;
  - (b) apart from those security interests, the holder has not done, or omitted to do, any act which would breach clause 1 if done or omitted during the escrow period; and
  - (c) a release of those security interests is attached.
7. If item 8 of the schedule is not completed or is marked "nil" or "n/a" (or something equivalent), the holder warrants that the holder has not created, or agreed to create, any security interests over the restricted securities.
8. If item 9 of the schedule is completed, the holder and each controller warrant that:
- (a) full particulars of security interests which have been created over the controller interests are set out in item 9;
  - (b) apart from those security interests, the controller has not done, or omitted to do, any act which would breach clause 2 if done or omitted during the escrow period; and
  - (c) a release of those security interests is attached.



9. If item 9 of the schedule is not completed or is marked "nil" or "n/a" (or something equivalent), the holder and each controller warrant that the controller has not created, or agreed to create, any security interests over the controller interests.
10. A breach of any of these warranties is a breach of this deed.

---

## CONSEQUENCES OF BREACHING THIS DEED

11. If the holder or a controller breach this deed:
- (a) the holder and each controller must take the steps necessary to rectify the breach;
  - (b) the entity must take the steps necessary to enforce the agreement;
  - (c) the entity must refuse to acknowledge any disposal (including, without limitation, to register any transfer) of any of the restricted securities in breach of this deed; and
  - (d) the holder of the restricted securities will cease to be entitled to any dividends or distributions, or to exercise any voting rights, in respect of the restricted securities for so long as the breach continues.

---

## AMENDMENT

12. This deed must not be terminated, changed or waived without ASX's written consent.

---

## COUNTERPARTS

13. This deed may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of this deed. Without limiting the foregoing, if the signatures on behalf of one party are on different counterparts, this shall be taken to be, and have the same effect as, signatures on the same counterpart and on a single copy of this deed.

---

## JURISDICTION

14. The laws of the State of New South Wales apply to this deed. We submit to the exclusive jurisdiction of the courts of that State.

---

## DEFINITIONS AND INTERPRETATION

In this agreement:

**ASX** means ASX Limited.

**controller** has the same meaning as in the listing rules.

**controller interests** means the securities or other rights or interests through which a controller controls, or has a substantial economic interest in, the restricted securities of the holder of the restricted securities, full particulars of which are set out in item 7 of the schedule.

**escrow period** means the period starting on the date set out in item 4 of the schedule and ending on the date set out in item 5 of the schedule.

**listing rules** mean the ASX Listing Rules, as in force from time to time.

**restricted securities** means the securities set out in item 6 of the schedule and any securities attaching to or arising out of those securities that are restricted securities under the listing rules.

The singular includes the plural and vice versa.

A reference to a party includes its successors, personal representatives and transferees.

Other words and expressions defined in the listing rules, and not in this deed, have the meanings given to them in the listing rules.

Every warranty or agreement (expressed or implied) in which more than one person joins, binds them individually and any combination of them as a group.

---

## SCHEDULE

---

**1. Item 1 Entity's name and address**

[INSERT]

**2. Item 2 Holder's name and address**

[INSERT]

**3. Item 3 Each controller's name and address**

[INSERT]

**4. Item 4 Escrow period start date:**

The date on which quotation of securities commences.

**5. Item 5 Escrow period end date:**

24 months after the date on which quotation of securities commences.

**6. Item 6 Particulars of restricted securities:**

[NUMBER] fully paid ordinary shares in the capital of the entity.

**7. Item 7 Particulars of controller interests:**

[INSERT].

**8. Item 8 Particulars of security interests over restricted securities:**

Not applicable

**9. Item 9 Particulars of security interests over controller interests:**

Not applicable

Dated this                      day of December 2021

**EXECUTED AS A DEED by** )  
**FIREBRICK PHARMA LIMITED** )  
**ACN 157 765 896** )  
in accordance with section 127 of the )  
*Corporations Act 2001 (Cth):* )

Signature of director

Signature of director/company secretary

Name of director

Name of director/company secretary

**EXECUTED AS A DEED** by \_\_\_\_\_ )  
**[INSERT]** \_\_\_\_\_ )  
in accordance with the constituent \_\_\_\_\_ )  
documents in its place of incorporation: \_\_\_\_\_ )

Signature of director

Signature of director/company secretary

Name of director

Name of director/company secretary